Statements (62)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:Company
|
gptkbp:bfsLayer |
6
|
gptkbp:bfsParent |
gptkb:Grifols_S._A.
|
gptkbp:accessories |
Forms supply partnerships with hospitals
|
gptkbp:acquisition |
gptkb:Biotest_AG
gptkb:Talecris_Biotherapeutics |
gptkbp:advocates_for |
Engages in patient advocacy efforts
|
gptkbp:awards |
Received multiple industry awards
|
gptkbp:ceo |
Victor Grifols
|
gptkbp:clinical_trial |
Conducts clinical trials for new therapies
Participates in international clinical trials Conducts clinical research in immunology |
gptkbp:collaborations |
Collaborates with research institutions
|
gptkbp:community_engagement |
Supports local communities
|
gptkbp:distribution |
Distributes products globally
|
gptkbp:economic_impact |
Expanding into emerging markets
|
gptkbp:employees |
over 24,000
|
gptkbp:focus |
Blood plasma collection
|
gptkbp:founded |
gptkb:1940
|
gptkbp:founder |
gptkb:Victor_Grifols_Roura
|
gptkbp:global_presence |
Strong global presence in healthcare
|
gptkbp:headquarters |
gptkb:Barcelona,_Spain
|
gptkbp:healthcare |
Contributes to global health initiatives
|
https://www.w3.org/2000/01/rdf-schema#label |
Grifols Biologicals
|
gptkbp:industry |
Pharmaceuticals
Utilizes biomanufacturing processes |
gptkbp:innovation |
Focuses on product innovation in therapies.
Innovates in plasma fractionation technology |
gptkbp:investment |
Invests in new technologies
|
gptkbp:leadership |
Leads in the plasma-derived therapies market
|
gptkbp:market |
Significant market share in plasma products
|
gptkbp:operates_in |
over 30 countries
|
gptkbp:partnership |
gptkb:charity
Partnerships with universities Collaborates with healthcare providers |
gptkbp:philanthropy |
Engages in philanthropic activities
|
gptkbp:product_line |
Factor VIII
Albumin Hyperimmune globulins IVIG (Intravenous Immunoglobulin) SCIG (Subcutaneous Immunoglobulin) |
gptkbp:products |
Plasma-derived medicines
Emphasizes quality control in production Focuses on product development for rare diseases |
gptkbp:provides_information_on |
Develops clinical guidelines for treatment
|
gptkbp:regulatory_compliance |
Complies with FDA regulations
Complies with EMA regulations Has a dedicated regulatory affairs team |
gptkbp:research |
Invests in biotechnology research
|
gptkbp:research_and_development |
Invests heavily in R& D
|
gptkbp:revenue |
€5.3 billion (2020)
|
gptkbp:safety_features |
Ensures product safety and efficacy
|
gptkbp:scholarships |
Provides patient support programs
|
gptkbp:social_responsibility |
Strong commitment to CSR
|
gptkbp:stock_exchange |
gptkb:NASDAQ
|
gptkbp:subsidiary |
gptkb:Grifols_Diagnostic_Solutions
|
gptkbp:supply_chain |
Maintains a robust supply chain
Implements effective supply chain management |
gptkbp:sustainability_initiatives |
Focuses on sustainability in operations
|
gptkbp:training |
Offers extensive employee training programs
Provides clinical education for healthcare professionals |
gptkbp:website |
www.grifols.com
|